201. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
- Author
-
Mohty M, Szydlo RM, Yong AS, Apperley JF, Goldman JM, and Melo JV
- Subjects
- Acute Disease, Adolescent, Adult, Child, Child, Preschool, Female, Gene Expression, Graft vs Host Disease immunology, HLA Antigens, Humans, Leukemia, Myeloid, Chronic-Phase genetics, Leukemia, Myeloid, Chronic-Phase immunology, Leukemia, Myeloid, Chronic-Phase therapy, Male, Middle Aged, Polycomb Repressive Complex 1, Prognosis, Siblings, Graft vs Host Disease etiology, Graft vs Host Disease genetics, Nuclear Proteins genetics, Proto-Oncogene Proteins genetics, Repressor Proteins genetics, Stem Cell Transplantation adverse effects
- Abstract
Expression of CD7, ELA-2, PR-3, and the polycomb group gene BMI-1 reflects the intrinsic heterogeneity and predicts prognosis of patients with chronic myeloid leukemia (CML) who were not treated with allogeneic stem cell transplantation (allo-SCT). This study investigated whether expression of these genes determined outcome following allo-SCT in a cohort of 84 patients with chronic-phase (CP) CML. We found that patients expressing BMI-1 at a "high" level before allo-SCT had an improved overall survival (P = .005) related to a reduced transplantation-related mortality. In multivariate analysis, when adjusted for the European Group for Blood and Marrow Transplantation (EBMT)-Gratwohl score and other prog-nostic factors, there was an independent association between BMI-1 expression and grades 2 to 4 acute graft-versus-host disease (relative risk [RR] = 2.85; 95% confidence interval [CI], 1.3-6.4; P = .011), suggesting that BMI-1 measured prior to allo-SCT can serve as a biomarker for predicting outcome in patients with CP-CML receiving allo-SCT, and may thus contribute to better therapeutic decisions.
- Published
- 2008
- Full Text
- View/download PDF